Engleman Edgar's Form 4 filing
Bolt Biotherapeutics, Inc.BOLT · filed Nov 20, 2023
- Accession no.
- 0001209191-23-056185
- Filed
- Nov 20, 2023
- Trade date
- Nov 16-20, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market sales total $45.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Engleman EdgarCIK 0001227162 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2023 | Common Stock | SSaleDisposed | −7,531 | $0.96F1 | −$7,229.76 | 1,989,685 | Indirect | |
| Nov 17, 2023 | Common Stock | SSaleDisposed | −8,211 | $0.93F3 | −$7,636.23 | 1,981,474 | Indirect | |
| Nov 20, 2023 | Common Stock | SSaleDisposed | −27,465 | $0.92F4 | −$25,267.8 | 1,954,009 | Indirect | |
| Nov 16, 2023 | Common Stock | SSaleDisposed | −1,040 | $0.96F1 | −$998.4 | 274,749 | Indirect | |
| Nov 17, 2023 | Common Stock | SSaleDisposed | −1,134 | $0.93F3 | −$1,054.62 | 273,615 | Indirect | |
| Nov 20, 2023 | Common Stock | SSaleDisposed | −3,792 | $0.92F4 | −$3,488.64 | 269,823 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F3
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.
Referenced by the price of 2 transactions in Table I.